P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
Kevin C. Hart(Stanford University), Maya F. Kotturi(Alameda Hospital), Liqin Liu(Xinjiang Agricultural University), Paul R. Hinton(IGM Biosciences (United States)), Rong Deng(IGM Biosciences (United States)), Stephen F. Carroll(IGM Biosciences (United States)), Maya K. Leabman(IGM Biosciences (United States)), Keyu Li(Sichuan University), Bruce A. Keyt, Genevive Hernandez(Sutro Biopharma (United States)), Angus M. Sinclair(LabGenius (United Kingdom)), Daniel Santos(IGM Biosciences (United States)), Deepal Pandya(IGM Biosciences (United States)), Thomas Manley(IGM Biosciences (United States)), Albert F. Candia(Dynavax Technologies (United States)), Yinghui Guan(Harbin Medical University)
Cited by 0
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
|The Journal of Infectious Diseases|1999|611
Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution.
|Proceedings of the National Academy of Sciences|1986|518
Subtype and pathway specific responses to anticancer compounds in breast cancer
|Proceedings of the National Academy of Sciences|2011|505